The global impact of Precision Medicine Group.
As it happens.
Impact, observations, and insights on the evolving healthcare landscape.
PROMISING RESULTS DERIVED FROM THE PIVOTAL PHASE 3 TAPPAS TRIAL OF TRC105 AND VATRIENT® IN PATIENTS WITH ADVANCED ANGIOSARCOMA
HOUSTON, TX – November 14, 2018 – Precision for Medicine and TRACON Pharmaceuticals (NASDAQ:TCON) announced today the presentation of biomarker results from the TAPPAS phase 3 clinical trial that utilized ApoCell’s proprietary circulating tumor cell (CTC) enrichment system, ApoStream. The study, titled Detection of Endoglin-Expressing CTCs in Patients Enrolled in an Adaptive Enrichment Phase 3 Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients with Advanced Angiosarcoma (TAPPAS), is the first of its kind to show the detection and capture of CTCs from angiosarcoma cancer patients. Interim study results were presented at the Connective Tissue Oncology Society (CTOS) annual meeting in Rome, Italy. (more…)
On Wednesday, September 26th at 10:00am PDT/1:00pm EDT please join us for a special, live webinar:
Navigating the FDA’s Final Guidance on HCEI and PIE:
Value Communication That Works
New announced research finds Epiontis ID™ technology can advance newborn screening as well as treatment of HIV patients in low-resource countries. (more…)
TAPPING FORMER PAYER DECISION MAKERS BOYCE, HONCZ AND OYEKAN
BRINGS UNRIVALED INSIGHTS TO CLIENTS
APRIL 18th, 2018 – New York, NY – Precision for Value, the market leader in supporting global pharmaceutical and life sciences companies in demonstrating the value and outcomes of innovative medical products, today announced significant additions to its Payer Strategy Team with the hiring of former payer executives Marylou Buyse, Joe Honcz, and Elizabeth Oyekan. (more…)
Payer, Health System and Channel influences driving utilization patterns of specialty products in Local Markets will be the focus of Larry Blandford and Ashwin Athri’s presentation at sPCMA March 5 in Orlando, Florida. Identifying such influences, they note, can help guide interventions and go to market strategies.
Jeremy Schafer, director of Precision’s Payer Access Solutions, weighs in on the concern of payer coverage for Dermira’s acne topical treatment. (more…)
PHE Scientific Advisor Anupam Jena, coauthor of a new study on preeclampsia in the September issue of American Journal of Obstetrics & Gynecology, discussed the study’s findings and the growing economic impact of the condition with the Orlando Sentinel’s Amelia Cheatham. (more…)
Denver (3-30-17)—The oncology landscape is rapidly evolving. A Pharmaceutical Research and Manufacturers of America report noted that 836 oncology drugs and vaccines are in the pipeline, 123 of which are for lung cancer, and 80% of pipeline agents are potential first-in-class therapies. Because of this, existing treatment paradigms are regularly upset. In addition, oncology costs continue to grow, with a reported $105 billion spent globally in 2015 and projected to rise 7.5% to 11.5% annually through 2020. In response, payers are using clinical pathways, preferred product and exclusion lists, and value assessment framework tools for better management of costs and care. Value-based risk sharing models among payers, providers and pharmaceutical manufacturers are also evolving.
Precision Health Economics’ Dana Goldman addresses the firestorm created by Mylan’s dramatic price hikes for their EpiPen in a new commentary published in STAT News: “To Prevent Another EpiPen Controversy, the Government Should Step In.”